In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PEOPLE - Changes at JenaValve Technology:

This article was originally published in Clinica

Executive Summary

Germany's JenaValve Technology has established a scientific advisory board, appointing eight members with immediate effect. It is headed by Professor Hans-Reiner Figulla, a cardiologist and co-founder and inventor at the Munich-based minimally-invasive aortic valve replacement systems developer. The other members are: fellow co-founder and inventor Dr Markus Ferrari; stent catheter consultant Dr Younes Boudjemline (Necker Hospital, Paris); Professor Junbo Ge, co-chair of the Shanghai Institute of Cardiovascular Diseases and president of the Shanghai Society of Cardiology; Professor Martin Rothman, director of cardiac R&D at London's Barts hospital; Professor Ziyad Hijazi, of Chicago's Rush University; Professor Jan Gummert, director of cardiothoracic surgery at Friedrich Schiller University Jena, Germany; and Professor Horst Sievert, director of the CardioVascular Center, Frankfurt.

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Topics

UsernamePublicRestriction

Register

MT049513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel